Shanghai fine-chemistry CO., Ltd

Based on technology,Create the future.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Intermediates

1297538-32-9 ODM-201 API C19H19ClN6O2 829-313-8

1297538-32-9 ODM-201 API C19H19ClN6O2 829-313-8

  • 1297538-32-9 ODM-201 API C19H19ClN6O2 829-313-8
1297538-32-9 ODM-201 API C19H19ClN6O2 829-313-8
Product Details:
Place of Origin: China
Brand Name: RUN
Certification: IOS9001
Model Number: RUN-Z
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Price: inquiry
Packaging Details: 10g 50g 100g 500g 1kg
Delivery Time: 3-7 days
Payment Terms: T/T, MoneyGram, BTCcoin
Supply Ability: 1kg --100kg
Contact Now
Detailed Product Description
Product Name: ODM-201 Synonyms: CS-1565;ODM-201(Darolutamide);N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide;0DM021;BAY-1841788;ODM-021;0DM021;ODM 021;ODM 021;ODM-021;ODM-201
CAS: 1297538-32-9 MF: C19H19ClN6O2
MW: 398.85 EINECS: 829-313-8
Boiling Point: 719.5±60.0 °C(Predicted) Density: 1.41±0.1 G/cm3(Predicted)
Purity: 99%
High Light:

1297538-32-9 Pharmaceutical Intermediates

,

API Pharmaceutical Intermediates

,

C19H19ClN6O2 Pharmaceutical Intermediates

SECTION 1: Basic information

ODM-201 Basic information
Product Name: ODM-201
Synonyms: CS-1565;ODM-201(Darolutamide);N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide;0DM021;BAY-1841788;ODM-021;0DM021;ODM 021;ODM 021;ODM-021;ODM-201
CAS: 1297538-32-9
MF: C19H19ClN6O2
MW: 398.85
EINECS: 829-313-8
Product Categories: API
Mol File: 1297538-32-9.mol
ODM-201 Structure
 
ODM-201 Chemical Properties
Boiling point 719.5±60.0 °C(Predicted)
density 1.41±0.1 g/cm3(Predicted)
pka 11.10±0.10(Predicted)
 
 
ODM-201 Usage And Synthesis
Description ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.
References Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007. Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013. Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85.

 

Contact Details
Shanghai fine-chemistry CO., Ltd

Contact Person: Mr. Dr. Zhang

Tel: +8613636696795

Send your inquiry directly to us (0 / 3000)

Other Products